Avacta to present promising new data from Affimer® and pre|CISIONTM platform assets at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
05 October 2023 - 5:00PM
5 October 2023
Avacta Group plc
(“Avacta” or the “Group” or the “Company”)
Avacta to present promising new data from
Affimer® and pre|CISIONTM
platform assets at AACR-NCI-EORTC International Conference
on Molecular Targets and Cancer Therapeutics
- AVA3996: FAP-α-activated proteasome
inhibitor from pre|CISIONTM platform concentrates proteasome
inhibitor payload in the tumour, increasing the therapeutic index
of this class of drugs
- AVA032: anti-PD-L1
Affimer® fused to IL-15 demonstrates encouraging
in vitro and in vivo efficacy
Avacta Group plc (AIM: AVCT), a life sciences
company focused on improving healthcare outcomes through targeted
cancer treatments and diagnostics, today announces that it will be
presenting two posters at the AACR-NCI-EORTC International
Conference on Molecular Targets and Cancer Therapeutics, taking
place on 11-15 October 2023 in Boston Massachusetts.
Details of the poster presentations are as
follows:
Abstract title: AVA3996,
a novel pre|CISION™ medicine, targets a warhead to the tumor
microenvironment via Fibroblast Activation Protein (“FAP”) mediated
cleavage to elicit tumor cell kill
Poster
number:
C169Session:
Poster Session
C Session
date and time:
Saturday, October 14 | 12:30 pm-4:00 pmSession
location:
Level 2, Exhibit Hall D
Abstract title: A novel,
tumor-targeted immunocytokine comprising an anti-PD-L1 Affimer®
fused to IL-15 exhibits potent anti-tumor activity
Poster
number:
A077Session:
Poster Session
A Session
date and time:
Thursday, October 12 | 12:30 pm-4:00 pmSession
location:
Level 2, Exhibit Hall D
Dr Fiona McLaughlin, Chief Scientific
Officer of Avacta commented:“We look forward to presenting
the promising new data from Avacta’s Therapeutics platform assets
at this conference. As disclosed in the Company’s announcement on
19 September 2023, our lead asset AVA6000 continues to advance
through the clinic at pace. We are simultaneously conducting
IND-enabling studies for promising assets derived from the
pre|CISIONTM and Affimer® platforms. The data to be presented
showcases the potential of our two therapeutic platforms to
generate further high value clinical assets.
“AVA3996, a FAP-α-activated proteasome inhibitor
based on our pre|CISIONTM technology, demonstrates targeted killing
of cancer cells in vitro and, by concentrating the active warhead
in the tumour, reduces systemic toxicity associated with this class
of drug.
“AVA032, our anti-PD-L1
Affimer® fused to the pro-inflammatory cytokine
interleukin 15 (IL-15) displays encouraging efficacy when tested in
multiple models of immunomodulation, stimulating a potent immune
response and reversing the immunosuppressive tumour
microenvironment.”
Further information regarding the conference can
be found on the ACCR’s website here:
https://www.aacr.org/meeting/aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics-2/
The posters will be available to view following
the conference here:
https://avacta.com/about/scientific-resources/
-Ends-
For further information from Avacta
Group plc, please contact:
Avacta Group
plcAlastair Smith, Chief Executive OfficerTony Gardiner,
Chief Financial OfficerMichael Vinegrad, Group Communications
Director |
Tel: +44 (0) 1904 21 7070www.avacta.com |
Stifel Nicolaus Europe
Limited (Nomad and Broker)Nicholas Moore / Nick Adams /
Samira Essebiyea / Nick Harland / William Palmer-Brown |
Tel: +44 (0) 207 710 7600www.stifel.com |
Peel Hunt
(Broker)James Steel / Chris Golden / Patrick Birkholm |
Tel: +44 (0) 207 418 8900www.peelhunt.com |
ICR Consilium (Media and
IR)Mary-Jane Elliott / Jessica Hodgson / Sukaina
Virji |
avacta@consilium-comms.com |
About Avacta Group plc -
https://www.avacta.com
Avacta Group is a UK-based company focused on
improving healthcare outcomes through targeted cancer treatments
and diagnostics.
Avacta has two divisions: an oncology biotech
division harnessing proprietary therapeutic platforms to develop
novel, highly targeted cancer drugs, and a diagnostics division,
which is executing on an M&A led growth strategy to create a
full-spectrum diagnostics business focused on supporting healthcare
professionals and broadening access to testing. Avacta’s two
proprietary platforms, Affimer® and pre|CISION™ underpin its cancer
therapeutics whilst the diagnostics division leverages the Affimer®
platform to drive competitive advantage in its markets.
The pre|CISION™ platform modifies chemotherapy
to be activated only in the tumour tissue, reducing systemic
exposure and toxicity. This is achieved by harnessing an enzyme
called FAP which is highly upregulated in most solid tumours
compared with healthy tissues, turning chemotherapy into a
“precision medicine”. The lead pre|CISION™ programme, AVA6000 a
tumour activated form of doxorubicin, is in Phase 1 studies and has
shown dramatic improvement in safety compared with standard
doxorubicin, and early signs of clinical activity.
Affimer® is a novel biologic platform which has
significant technical and commercial advantages compared with
antibodies and is used both to develop advanced immunotherapies and
to improve the performance of immunodiagnostics.
With a balanced business and capital allocation
model: a high-value oncology pipeline supported by a revenue
generating, fast-growing diagnostics business, Avacta seeks to
create long-term shareholder value alongside patient benefit.
To register for news alerts by email go to
https://avacta.com/investors/investor-news-email-alerts/
About AVA3996
AVA3996 is a FAP-α-activated proteasome
inhibitor, based on the Company’s pre|CISIONTM technology platform.
AVA3996 has the potential to become a targeted cancer treatment for
various indications, overcoming cytotoxicity issues displayed when
the free, non-targeted form of proteasome inhibitor is systemically
administered to patients.
About AVA032
AVA032 is an anti-PD-L1
Affimer® fused to the cytokine interleukin 15
(“IL-15”). It carries improved properties compared to monoclonal
antibodies, currently used as cancer therapeutics, and works to
reverse the immunosuppressive tumour micro-environment, inducing a
lasting immune response aimed at stimulating a patient’s immune
system to destroy cancer cells.
Avacta (LSE:AVCT)
Historical Stock Chart
From Apr 2024 to May 2024
Avacta (LSE:AVCT)
Historical Stock Chart
From May 2023 to May 2024